Cargando…
Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France
BACKGROUND AND AIMS: The IMbrave150 clinical trial assessed the efficacy and safety of atezolizumab in combination with bevacizumab (ATZ+BVA) versus sorafenib in adults with advanced/unresectable hepatocellular carcinoma, who have not received prior systemic treatment. Our aim was to assess the cost...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847974/ https://www.ncbi.nlm.nih.gov/pubmed/36652428 http://dx.doi.org/10.1371/journal.pone.0280442 |
_version_ | 1784871596552355840 |
---|---|
author | Gaugain, Loïg Cawston, Hélène Dubois de Gennes, Coline Sanchez Alvares, Javier Nahon, Pierre Mazaleyrat, Benjamin Le Dissez, Clément |
author_facet | Gaugain, Loïg Cawston, Hélène Dubois de Gennes, Coline Sanchez Alvares, Javier Nahon, Pierre Mazaleyrat, Benjamin Le Dissez, Clément |
author_sort | Gaugain, Loïg |
collection | PubMed |
description | BACKGROUND AND AIMS: The IMbrave150 clinical trial assessed the efficacy and safety of atezolizumab in combination with bevacizumab (ATZ+BVA) versus sorafenib in adults with advanced/unresectable hepatocellular carcinoma, who have not received prior systemic treatment. Our aim was to assess the cost-effectiveness of ATZ+BVA versus sorafenib in France based on an updated prices and considering French National real-world data, to confirm the initial recommendations from the Heath Technology Assessment submission published in 2021, and provide additional visibility to decision-makers reflecting current clinical practice. METHODS: A partition survival model was developed to project clinical outcomes, quality of life, and costs of patients with HCC treated with ATZ+BVA versus sorafenib over a lifetime horizon. Survival outcomes were extrapolated via parametric functions for both treatment strategies. Quality of life (EQ-5D-5L, French tariffs) were sourced from IMbrave150. The Guyot method was considered as a scenario analysis by integrating retrospective real-world data extracted from the French Health Insurance Database to refine long term survival extrapolations. RESULTS: In the reference case, ATZ+BVA was associated with 0.61 additional Quality Adjusted Life Years (QALYs) compared to sorafenib (1.95 vs 1.35), and an incremental cost of €92,704. The incremental cost-utility ratio (ICUR) was 152,974 €/QALY gained. Adjusting the survival curves with French external evidence led to a 14% ICUR reduction (131,163 €/QALY). CONCLUSIONS: ATZ+BVA is a cost-effective strategy based on the range recently published for the value of a QALY in France and offers better chances of survival to patients. |
format | Online Article Text |
id | pubmed-9847974 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-98479742023-01-19 Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France Gaugain, Loïg Cawston, Hélène Dubois de Gennes, Coline Sanchez Alvares, Javier Nahon, Pierre Mazaleyrat, Benjamin Le Dissez, Clément PLoS One Research Article BACKGROUND AND AIMS: The IMbrave150 clinical trial assessed the efficacy and safety of atezolizumab in combination with bevacizumab (ATZ+BVA) versus sorafenib in adults with advanced/unresectable hepatocellular carcinoma, who have not received prior systemic treatment. Our aim was to assess the cost-effectiveness of ATZ+BVA versus sorafenib in France based on an updated prices and considering French National real-world data, to confirm the initial recommendations from the Heath Technology Assessment submission published in 2021, and provide additional visibility to decision-makers reflecting current clinical practice. METHODS: A partition survival model was developed to project clinical outcomes, quality of life, and costs of patients with HCC treated with ATZ+BVA versus sorafenib over a lifetime horizon. Survival outcomes were extrapolated via parametric functions for both treatment strategies. Quality of life (EQ-5D-5L, French tariffs) were sourced from IMbrave150. The Guyot method was considered as a scenario analysis by integrating retrospective real-world data extracted from the French Health Insurance Database to refine long term survival extrapolations. RESULTS: In the reference case, ATZ+BVA was associated with 0.61 additional Quality Adjusted Life Years (QALYs) compared to sorafenib (1.95 vs 1.35), and an incremental cost of €92,704. The incremental cost-utility ratio (ICUR) was 152,974 €/QALY gained. Adjusting the survival curves with French external evidence led to a 14% ICUR reduction (131,163 €/QALY). CONCLUSIONS: ATZ+BVA is a cost-effective strategy based on the range recently published for the value of a QALY in France and offers better chances of survival to patients. Public Library of Science 2023-01-18 /pmc/articles/PMC9847974/ /pubmed/36652428 http://dx.doi.org/10.1371/journal.pone.0280442 Text en © 2023 Gaugain et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Gaugain, Loïg Cawston, Hélène Dubois de Gennes, Coline Sanchez Alvares, Javier Nahon, Pierre Mazaleyrat, Benjamin Le Dissez, Clément Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France |
title | Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France |
title_full | Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France |
title_fullStr | Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France |
title_full_unstemmed | Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France |
title_short | Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France |
title_sort | cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in france |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847974/ https://www.ncbi.nlm.nih.gov/pubmed/36652428 http://dx.doi.org/10.1371/journal.pone.0280442 |
work_keys_str_mv | AT gaugainloig costutilityanalysisofatezolizumabwithbevacizumabinuntreatedunresectableoradvancedhepatocellularcarcinomainfrance AT cawstonhelene costutilityanalysisofatezolizumabwithbevacizumabinuntreatedunresectableoradvancedhepatocellularcarcinomainfrance AT duboisdegennescoline costutilityanalysisofatezolizumabwithbevacizumabinuntreatedunresectableoradvancedhepatocellularcarcinomainfrance AT sanchezalvaresjavier costutilityanalysisofatezolizumabwithbevacizumabinuntreatedunresectableoradvancedhepatocellularcarcinomainfrance AT nahonpierre costutilityanalysisofatezolizumabwithbevacizumabinuntreatedunresectableoradvancedhepatocellularcarcinomainfrance AT mazaleyratbenjamin costutilityanalysisofatezolizumabwithbevacizumabinuntreatedunresectableoradvancedhepatocellularcarcinomainfrance AT ledissezclement costutilityanalysisofatezolizumabwithbevacizumabinuntreatedunresectableoradvancedhepatocellularcarcinomainfrance |